Please login to the form below

Not currently logged in
Email:
Password:

major depressive disorder

This page shows the latest major depressive disorder news and features for those working in and with pharma, biotech and healthcare.

Depression drug failure adds to Allergan's woes

Depression drug failure adds to Allergan's woes

Axe hangs over remaining monotherapy and suicidality trials. Allergan’s novel treatment for major depressive disorder (MDD) rapastinel has failed in three pivotal phase 3 studies. ... The misfiring of rapastinel is a major blow for the company’s most

Latest news

More from news
Approximately 6 fully matching, plus 52 partially matching documents found.

Latest Intelligence

  • Leo has its eyes on the prize Leo has its eyes on the prize

    condition and the promise of major therapeutic breakthroughs. ... major depressive disorder and iron-deficiency anaemia.

  • Pharma deals continue to slide Pharma deals continue to slide

    74.5 (upfront 65). Cerecor (US). J&J/Janssen (US). Asset acquisition. CERC-501 phase II oral kappa opioid receptor antagonist for adjunctive treatment of major depressive disorder.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Red Health

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics